NOVEL ANTIGENS FOR THE SERODIAGNOSIS OF HUMAN BABESIOSIS

用于人类巴贝斯虫病血清学诊断的新抗原

• 批准号: 2422889
• 负责人: Raymond Houghton
• 金额: $ 9.99万
• 依托单位: CORIXA CORPORATION
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-30 至 1998-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2422889
• 关键词: babesiosis; clinical research; diagnosis design /evaluation; human subject; protozoal antigen; recombinant proteins; serology /serodiagnosis

DESCRIPTION (Adapted from the Applicant's Abstract): This proposal discusses the production and implementation of peptide/recombinant antigens for the development of a serological assay for the diagnosis of human babesiosis, a tick-borne disease. Increased surveillance of tick borne infections has shown that many individuals infected with Lyme disease have co-infections with Babesia microti (agent of human babesiosis) and Ehrlichia both of which are potentially fatal in immunocompromised individuals any may impact blood transfusions. Since the treatment of B. microti infections (malaria-like intraerythrocytic parasite) is vastly different to Lyme disease there is a need for an accurate serology test to differentiate the two infections. B. microti specific peptides/recombinants will be used alone or in combination to develop an assay to supplement the currently available Lyme disease test. Development of specific antigens for B. microti for use in diagnosis improves our ability to detect tick-borne diseases and facilitates administration of the appropriate treatment. Advances have already been achieved at Corixa in identifying immunodominant recombinant antigens. This in combination with a collaboration with key investigator in the area of tick-borne diseases and access to an extensive serum bank accumulated through work on other infectious disease programs should enable the goals and objectives of this proposal to be achieved.

描述（根据申请人的摘要改编）：此提案 讨论肽/重组的生产和实施 抗原开发血清学测定法以诊断 人类巴布西病，一种tick虫疾病。提高tick的监视 传播感染表明，许多感染莱姆的人 疾病与Babesia Microti共同感染（人类的药物 巴布西症）和ehrlichia均可能致命 免疫功能低下的个体任何人都可能影响输血。自从 微芽孢杆菌感染的治疗（类似疟疾的肠内肠内感染 寄生虫）与莱姆病大不相同，需要 准确的血清学测试以区分两种感染。 B. microti 特定的肽/重组剂将单独使用或组合使用 开发一种补充当前可用的莱姆病试验的测定法。 开发用于诊断的小芽孢杆菌的特异性抗原 提高我们检测壁虱传播疾病并促进的能力 适当的治疗。进步已经 在Corixa鉴定免疫主导重组抗原方面实现。 这与与主要调查员合作的合作 tick传播疾病的区域并进入广泛的血清库 通过在其他传染病计划上的工作积累 启用该提案的目标和目标。